| Bioactivity | Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) [1]. |
| Invitro | Valanafusp alfa (HIRMAb-IDUA) 与 HIR 胞外结构域 (ECD) 结合，EC50 为 0.93±0.07 nM[2]。Valanafusp alfa (HIRMAb-IDUA) (0.3 μg/mL; 48 h) 与健康成纤维细胞相比，可使 Hurler 成纤维细胞中的糖氨基聚糖积累减少 70%[2]。 |
| In Vivo | Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) 慢性给药在所有剂量下都具有极好的安全性，并且对血浆或脑脊液的血糖控制没有影响[1]。Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) 在 Rhesus monkeys 体内稳定，清除率快，分布量大[1]。 |
| Name | Valanafusp alfa |
| CAS | 1815583-32-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Boado RJ, et al. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol. 2009 Oct 26;144(2):135-41. [2]. Boado RJ, et al. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008 Feb 1;99(2):475-84. |